EMA consults on revised guideline on active substance master file procedure
This article was originally published in SRA
The European Medicines Agency is consulting on proposed improvements to its guideline on how drug companies can compile an active substance master file (ASMF) and the "active substance section" of their dossiers for a marketing authorisation application or a marketing authorisation variation1.
You may also be interested in...
Remote inspections are here to stay, and global regulators are aligning efforts to develop consensus on how these should be conducted.
The Canadian medtech regulator has recommended updating its list of recognized medical device standards that manufacturers can rely on to demonstrate compliance with local safety, effectiveness and labeling requirements.
Reports from Norway about deaths in very frail, elderly patients soon after receiving Pfizer/BioNTech’s COVID-19 jab have drawn regulatory scrutiny. While the European Medicines Agency has launched an investigation, Australia is examining the need for specific warnings about risks of vaccination in the very frail elderly or terminally ill patients.